Source-grounded facts extracted from MESA LABORATORIES INC /CO/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lyndsey Crennen was appointed as Chief Accounting Officer at MESA LABORATORIES INC /CO/.
“On June 11, 2026, the board of directors (the “Board”) of Mesa Laboratories, Inc. (“Mesa” or the “Company”) approved the appointment of Lyndsey Crennen as the Chief Accounting Officer of the Company, effective as of her entry into the Employment Agreement described below.”
MESA LABORATORIES INC /CO/ reported financial results for three months ended March 31, 2026.
“On May 27, 2026, Mesa Laboratories, Inc. issued a press release relating to its results for the three and twelve months ended March 31, 2026.”
MESA LABORATORIES INC /CO/ reported financial results for fiscal year ended March 31, 2026.
“On May 27, 2026, Mesa Laboratories, Inc. issued a press release relating to its results for the three and twelve months ended March 31, 2026.”
MESA LABORATORIES INC /CO/ incurred credit facility of $97 million at a base rate or a SOFR rate, plus an applicable spread maturing April 5, 2029.
“On August 12, 2025, Mesa Laboratories, Inc. ("the "Company") drew $97 million under its existing Credit Facility.”
Moss Adams LLP resigned as auditor of MESA LABORATORIES INC /CO/.
“On June 3, 2025, Mesa Laboratories, Inc., (the "Company") was notified that Moss Adams LLP ("Moss Adams"), the Company's independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025. The combined audit practices operate as Baker Tilly US, LLP (“Baker Tilly”). In connection with the notification of the merger, Moss Adams has resigned as the auditors of the Company and the Audit Committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm.”
MESA LABORATORIES INC /CO/ amended Credit Agreement with syndicate of banks led by JPMorgan Chase Bank, N.A., as administrative agent (effective 2024-04-05).
“On April 5, 2024, Mesa Laboratories, Inc. (the “Company” “we” “us” or “our”) amended and restated its senior secured credit agreement (the “Credit Agreement”) with a syndicate of banks led by JPMorgan Chase Bank, N.A., as administrative agent.”
MESA LABORATORIES INC /CO/ reported third fiscal quarter ended December 31, 2023 results: revenue $53,473, net income $2,116, EPS $0.39 per diluted share of common stock.
“● Non-GAAP adjusted operating income excluding unusual items as a percentage of revenues increased sequentially to 22.4% Executive Commentary (amounts in thousands) “Revenues of $53,473 for the quarter decreased 1.5% as compared to the third quarter of fiscal year 2023 (“3Q23”), due primarily to a 9.0% core organic revenues (“core organic”) decrease which was”
Mark Capone was appointed as Director at MESA LABORATORIES INC /CO/.
“Effective January 5, 2024, the Board of Directors (“Board”) of Mesa Laboratories, Inc. (“Mesa ”), upon the recommendation of its Nominating and Governance Committee, voted to expand the size of the Board from six to seven members, and to appoint Mark Capone to fill the newly created seat.”
MESA LABORATORIES INC /CO/ reported second fiscal quarter ended September 30, 2023 results: revenue $53,165, net income $(1,230), EPS $(0.23) per diluted share.
“our Clinical Genomics division early in 3Q23 but was better than the first quarter for both revenues and AOI excluding unusual items. Total revenues for the second quarter were $53,165, which resulted in an organic revenue (“organic”) decline of 9.6% versus the same quarter in the prior year (“2Q23”), or a 5.0% sequential increase when compared to the first”
MESA LABORATORIES INC /CO/ amended revolving credit of $125.0 million with JPMorgan Chase Bank, N.A..
“Chase Bank, N.A., as administrative agent. The terms of the original credit agreement, as amended, have not changed, except: 1) The Revolving Commitment has been increased to $125.0 million, from $75.0 million; and 2) Certain administrative amendments have been made to accommodate changes in the business. As of the date of this Form 8-K, no amounts have been drawn”
MESA LABORATORIES INC /CO/ entered into Senior Secured Credit Agreement with JPMorgan Chase Bank, N.A. valued at Revolving Commitment increased to $125.0 million (effective 2023-10-05).
“On October 5, 2023, Mesa Laboratories, Inc. (the “Company”) amended its four-year senior secured credit agreement (the “Credit Agreement”) with the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.”
MESA LABORATORIES INC /CO/ engaged RSM US, LLP as its auditor.
“approved the engagement of RSM US, LLP (“RSM”) as the Company’s independent registered public accounting firm”
MESA LABORATORIES INC /CO/ dismissed Plante & Moran, PLLC as its auditor.
“In connection therewith, the Audit Committee dismissed Plante & Moran, PLLC (“Plante & Moran”) as the company’s independent registered public accounting firm, effective immediately. The decision to appoint RSM as the Company’s new independent registered public accounting firm resulted from a competitive request for proposal process after Plante & Moran notified the Audit Committee that Plante & Moran is evaluating whether to continue its Securities and Exchange Commission audit practice in the Company’s primary industry. During the two most recent fiscal years ended March 31, 2022 and March 31, 2023, and the subsequent interim period preceding RSM’s engagement, the Company has not consulted with RSM regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s fi”
MESA LABORATORIES INC /CO/: Shareholders approved and adopted Amended and Restated Articles of Incorporation to remove specific purposes, amend director exculpation provisions, and make non-substantive amendments (effective 2023-08-25).
“the shareholders approved and adopted amended and restated articles of incorporation of the Company (the “Amended and Restated Articles of Incorporation”) to: remove the specific purposes of the Company, amend the director exculpation provisions, and make certain non-substantive amendments to eliminate provisions that are no longer necessary.”
MESA LABORATORIES INC /CO/ reported the three months ended June 30, 2023 results: revenue $50,645, net income $(549), EPS $(0.10) per diluted share.
“Total revenues were $50,645, an increase of 0.4% compared to the first quarter of fiscal year 2023 (“1Q23”) as last year’s acquisition of Belyntic made a modest contribution to revenue. Operating loss decreased 85.5% to $ (664). Net loss was $(549), a decrease of 61.8% or $(0.10) per diluted share of common stock.”
John B. Schmieder departed as Director at MESA LABORATORIES INC /CO/.
“On May 3, 2023, John B. Schmieder, member of the Board of Directors (the “Board”), current Chair of the Nominating and Governance Committee, and member of the Audit Committee, informed the Board of Mesa Laboratories, Inc. that he has decided not to stand for re-election at the 2023 annual meeting of shareholders.”
MESA LABORATORIES INC /CO/ reported three and nine months ended December 31, 2022 results: revenue $54,287, net income $451, EPS $0.08 per diluted share.
“3 was 4.6% ● Operating income increased 235% ● Non-GAAP adjusted operating income 1 excluding unusual items decreased 7% Executive Commentary (amounts in thousands) “Revenues of $54,287 in the quarter resulted in an organic revenues decline of 2.1% for the quarter, heavily influenced by currency headwinds across the company, as well as COVID headwinds and the”
MESA LABORATORIES INC /CO/ shareholders approved Advisory vote on the frequency of future say-on-pay votes.
“The non-binding, advisory vote regarding the frequency of voting on the compensation paid to the Company's named executive officers was in favor of voting every one year: Every 1 Year Every 2 Years Every 3 Years Abstain Broker Non-Votes 4,330,300 6,130 43,642 2,849 296,490”
MESA LABORATORIES INC /CO/ reported three and six months ended September 30, 2022 results: revenue $58,749, net income $1,306, EPS $0.24 per diluted share.
“In comparison to the same quarter in the prior year (“2Q22”), revenues increased 64% to $58,749, operating income decreased 5% to $3,995 and net income was $1,306, a decrease of 65% or $0.24 per diluted share of common stock.”
Tony Tripeny was appointed as Director at MESA LABORATORIES INC /CO/.
“Effective June 23, 2022, Mesa Laboratories, Inc’s (“Mesa Labs”) Board of Directors (“Board”), upon the recommendation of the Nominating and Governance Committee appointed Tony Tripeny to its Board.”
Greg DiNoia was terminated as Senior Vice President of Commercial Operations at MESA LABORATORIES INC /CO/.
“Mesa Laboratories, Inc. (the “Company”) and Mr. Greg DiNoia, Senior Vice Persident of Commercial Operations, have agreed that Mr. DiNoia’s employment will be terminated and he will leave the company on June 30, 2022”
Shiraz Ladiwala was appointed as Director at MESA LABORATORIES INC /CO/.
“Effective October 28, 2021, Mesa Laboratories, Inc’s (“Mesa”) Board of Directors (“Board”) increased the size of Mesa’s Board from seven to eight members and upon the recommendation of the Nominating and Governance Committee, appointed Shiraz Ladiwala to fill the newly-created vacancy.”
David M. Kelly retired as Director at MESA LABORATORIES INC /CO/.
“On September 24, 2021, David M. Kelly informed Mesa Laboratories, Inc. (the “ Company ”) of his planned retirement from the Board of Directors of the Company, including the Compensation Committee, to be effective as of close of business on April 3, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.